PolyPid Ltd. (PYPD) |
| 4.41 -0.24 (-5.16%) 01-13 16:00 |
| Open: | 4.66 |
| High: | 4.68 |
| Low: | 4.26 |
| Volume: | 69,588 |
| Market Cap: | 45(M) |
| PE Ratio: | -1.57 |
| Exchange: | NASDAQ Global Market |
| Industry: | Biotechnology |
| Sector: | Healthcare |
| Technical analysis | ||||
![]() |
||||
| sell | buy | |||
| Resistance 2: | 4.97 |
| Resistance 1: | 4.56 |
| Pivot price: | 4.37 |
| Support 1: | 3.89 |
| Support 2: | 3.24 |
| 52w High: | 4.97 |
| 52w Low: | 2.3 |
PolyPid Ltd., a late-stage biopharma company, develops, manufactures, and commercializes products based on polymer-lipid encapsulation matrix (PLEX) platform to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in Phase III clinical trial for the prevention of sternal (bone) surgical site infections (SSIs), as well as for the prevention of abdominal (soft tissue) SSIs. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel.
| EPS | -2.810 |
| Book Value | 0.920 |
| PEG Ratio | 0.00 |
| Gross Profit | 0.000 |
| Profit Margin (%) | 0.00 |
| Operating Margin (%) | 0.00 |
| Return on Assets (ttm) | -87.9 |
| Return on Equity (ttm) | -390.5 |
Wed, 17 Dec 2025
PolyPid Appoints Brooke Story as Chairman Amid Strategic Growth - The Globe and Mail
Tue, 16 Dec 2025
PolyPid Appoints Veteran MedTech Leader Brooke Story as Chairman of the Board of Directors - GlobeNewswire
Tue, 16 Dec 2025
PolyPid Ltd. Appoints Brooke Story as Chairman of the Board of Directors - Quiver Quantitative
Wed, 03 Dec 2025
PolyPid Announces Positive FDA Pre-NDA Meeting Minutes for D-PLEX₁₀₀ Supporting NDA Submission - GlobeNewswire
Wed, 03 Dec 2025
PolyPid stock rises after FDA supports NDA submission for D-PLEX100 - Investing.com
Wed, 03 Dec 2025
PolyPid (Nasdaq: PYPD) to start D-PLEX100 rolling NDA after FDA pre-NDA meeting support - Stock Titan
|
StockChart iOS |
StoxlineLite iOS |
StoxlineLite iOS |
OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |